Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Core Insights - Nkarta, Inc. is set to present clinical data on its investigational therapy NKX019 at the ACR Convergence 2025 meeting, highlighting its potential in treating autoimmune diseases driven by pathogenic B cells [1][2]. Group 1: Clinical Data Presentation - NKX019 demonstrated robust pathogenic B-cell depletion and reconstitution of the B cell compartment in participants with non-Hodgkin lymphoma, indicating an immune reset [2]. - Preclinical studies showed NKX019 effectively depletes pathogenic B cells in both in vivo lymphoma models and in vitro autoimmune disease models, with the ability to traffic to lymphoid organs and disseminate across multiple tissues [2]. Group 2: Market Need and Therapeutic Potential - Millions of patients in the U.S. suffer from autoimmune diseases driven by pathological B cells, with current treatments often inadequate or toxic, leaving limited options [4]. - Nkarta's engineered allogeneic NK cells aim to selectively deplete disease-driving B cells without inducing limiting toxicities, presenting a novel therapeutic approach for B-cell driven autoimmune diseases [4]. Group 3: Presentation Details - The poster presentation titled "NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease" will take place on October 26 from 10:30 AM to 12:30 PM CT [4]. - Nkarta will also exhibit at booth 1801 during the conference, providing opportunities for attendees to discuss the company's clinical programs [4]. Group 4: Company Overview - Nkarta is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf NK cell therapies for autoimmune diseases, utilizing a cell expansion and cryopreservation platform combined with proprietary cell engineering technologies [5].